<DOC>
	<DOCNO>NCT02810743</DOCNO>
	<brief_summary>Investigator-initiated , international , multicentre , randomize , open-label , ( neo ) adjuvant phase III study target population ( stage III , HER2-negative , BRCA1-like breast cancer patient ) compare optimize standard-dose chemotherapy intensify , alkylating chemotherapy stem cell rescue .</brief_summary>
	<brief_title>Substantially Improving Cure Rate High-risk BRCA1-like Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Women men stage III adenocarcinoma breast harboring sign breast cancer feature homologous recombination deficiency ( HRD ) Age 1865 year The tumor must HER2negative Treatment must start within 8 week last surgical resection Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Previous radiation therapy Previous chemotherapy Any previous treatment PARPinhibitor , include olaparib Preexisting neuropathy cause excess Grade 1 Chronic concomitant use know strong moderate CYP3A inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>